Equities analysts expect that Viewray Inc (NASDAQ:VRAY) will announce $21.77 million in sales for the current fiscal quarter, according to Zacks. Five analysts have issued estimates for Viewray’s earnings, with the highest sales estimate coming in at $28.70 million and the lowest estimate coming in at $18.82 million. Viewray posted sales of $19.92 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 9.3%. The firm is scheduled to issue its next quarterly earnings report on Monday, March 11th.
According to Zacks, analysts expect that Viewray will report full-year sales of $80.18 million for the current fiscal year, with estimates ranging from $79.12 million to $81.53 million. For the next fiscal year, analysts anticipate that the business will report sales of $139.10 million, with estimates ranging from $125.80 million to $159.42 million. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that cover Viewray.
Viewray (NASDAQ:VRAY) last issued its quarterly earnings data on Thursday, November 8th. The company reported ($0.39) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.22) by ($0.17). The company had revenue of $17.70 million during the quarter, compared to the consensus estimate of $17.77 million. Viewray had a negative net margin of 105.09% and a negative return on equity of 105.63%. Viewray’s revenue for the quarter was up 45.1% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.19) earnings per share.
In other Viewray news, CEO Scott William Drake purchased 60,000 shares of the stock in a transaction that occurred on Tuesday, November 13th. The shares were acquired at an average cost of $6.47 per share, with a total value of $388,200.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Shahriar Matin purchased 25,000 shares of the stock in a transaction that occurred on Tuesday, November 13th. The shares were acquired at an average cost of $6.47 per share, for a total transaction of $161,750.00. The disclosure for this purchase can be found here. 43.93% of the stock is currently owned by company insiders.
A number of large investors have recently added to or reduced their stakes in VRAY. Perceptive Advisors LLC increased its position in Viewray by 4,833.3% during the third quarter. Perceptive Advisors LLC now owns 3,700,000 shares of the company’s stock worth $34,632,000 after acquiring an additional 3,625,000 shares during the period. Fosun International Ltd increased its position in Viewray by 27.9% during the second quarter. Fosun International Ltd now owns 13,768,556 shares of the company’s stock worth $95,278,000 after acquiring an additional 3,000,581 shares during the period. HealthCor Management L.P. bought a new position in Viewray during the third quarter worth about $23,609,000. FMR LLC increased its position in Viewray by 36.9% during the second quarter. FMR LLC now owns 7,670,767 shares of the company’s stock worth $53,082,000 after acquiring an additional 2,069,086 shares during the period. Finally, BlackRock Inc. increased its position in Viewray by 51.9% during the third quarter. BlackRock Inc. now owns 4,501,045 shares of the company’s stock worth $42,130,000 after acquiring an additional 1,538,108 shares during the period. 98.28% of the stock is currently owned by institutional investors and hedge funds.
Shares of VRAY traded down $0.55 during trading hours on Friday, hitting $6.43. The company had a trading volume of 20,535 shares, compared to its average volume of 1,560,316. The firm has a market capitalization of $642.35 million, a PE ratio of -6.22 and a beta of 1.12. Viewray has a 12 month low of $5.80 and a 12 month high of $13.21. The company has a debt-to-equity ratio of 0.25, a current ratio of 6.47 and a quick ratio of 5.56.
ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.
See Also: Trading Strategy Methods and Types
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Viewray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viewray and related companies with MarketBeat.com's FREE daily email newsletter.